IBM halting sales of Watson AI tool for drug discovery

Citing lackluster financial performance, IBM is halting development and sales of a product that uses its Watson artificial intelligence software to help pharmaceutical companies discover new drugs, according to a person familiar with the company’s internal decision-making. The decision to shut down sales of Watson for Drug Discovery marks the highest-profile retreat in the company’s effort to apply artificial intelligence to various areas of health care. What’s biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage networking events and panel discussions across the country

Monthly subscriber-only live chats with our reporters and experts in the field

Discounted tickets to industry events and early-bird access to industry Technology Correspondent

Casey covers the companies disrupting biopharma and health care.

Source: www.statnews.com